Hemophagocytic syndrome associated with pembrolizumab therapy successfully controlled by cyclosporin

J Dermatol. 2020 Dec;47(12):e422-e423. doi: 10.1111/1346-8138.15566. Epub 2020 Aug 29.

Authors

Yuzuki Sakai¹, Kenta Nakamura¹, Hirotaka Midorikawa¹, Kana Osawa¹, Takushi Shirai¹, Tasuku Sano¹, Yukiko Kiniwa¹, Hideyuki Nakazawa², Ryuhei Okuyama¹

Affiliations

¹ Department of Dermatology, Shinshu University School of Medicine, Matsumoto, Japan.
² Division of Hematology, Internal Medicine, Shinshu University School of Medicine, Matsumoto, Japan.

PMID: 32860242
DOI: 10.1111/1346-8138.15566

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Monoclonal, Humanized
Cyclosporine* / therapeutic use
Humans
Immunosuppressive Agents / therapeutic use
Lymphohistiocytosis, Hemophagocytic* / diagnosis
Lymphohistiocytosis, Hemophagocytic* / drug therapy

Substances

Antibodies, Monoclonal, Humanized
Immunosuppressive Agents
Cyclosporine
pembrolizumab